Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
Categories
Web Exclusives
Web Exclusive Articles
Webinars
Search ...
ASH 2015 - Multiple Myeloma
Management of Infusion-Related Reactions Associated with Daratumumab Monotherapy in RRMM
ASH 2015 - Multiple Myeloma
Conference Correspondent
Researchers presented data relating to the management of infusion-related reactions (IRRs) associated with single-agent daratumumab treatment in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in the open-label, multicenter, phase 2 Sirius study.
Read More
Patient Preferences on Treatment Attributes in MM
ASH 2015 - Multiple Myeloma
Conference Correspondent
Researchers reported results of an online survey that examined the preferences of patients with multiple myeloma (MM) on route of administration and individual treatment-related adverse events.
Read More
The Relevance of Minimal Residual Disease Monitoring in Elderly Multiple Myeloma Patients
ASH 2015 - Multiple Myeloma
Conference Correspondent
Researchers reported on a study that assessed the clinical utility of minimal residual disease (MRD) monitoring in elderly patients with multiple myeloma (MM) included in the PETHEMA/GEM2010MAS65 trial.
Read More
Final OS Analysis of Panorama 1 Trial of Panobinostat/Bortezomib/Dexamethasone in RRMM
ASH 2015 - Multiple Myeloma
Conference Correspondent
Researchers present the final data for the secondary end point of overall survival across the entire study population of the phase 3 clinical trial PANORAMA 1, which evaluated panobinostat in combination with bortezomib and dexamethasone. Overall survival was not statistically significant.
Read More
Bortezomib/Melphalan/Prednisolone Induction Therapy Followed by Lenalidomide/Dexamethasone Consolidation and Lenalidomide Maintenance in Transplant-Ineligible Patients with Newly Diagnosed MM
ASH 2015 - Multiple Myeloma
Conference Correspondent
The VISTA study demonstrated good tolerability of VMP; however, in a subsequent phase 2 trial, there was a higher rate of treatment discontinuation than expected. In this study, investigators demonstrated lowering the intensity of VMP proved to be both safe and effective for newly diagnosed multiple myeloma (NDMM).
Read More
Search ...
Home
Issues
Latest Issue
Issue Archive
Special Issues
Categories
Web Exclusives
Web Exclusive Articles
Webinars
Subscribe to Value-Based Care in Neurology
Stay up to date with personalized medicine by subscribing to receive the free
VBCN
e‑Newsletter.
First Name*
Last Name
Email*
Please verify your request*
SUBSCRIBE